The Cancer Letter

Inside information on cancer research and drug development

Guest Editorial

USPSTF breast cancer screening guidelines are clear, concise; now let’s address gaps in quality

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
BYLINEDOWNLOAD PDFTABLE OF CONTENTS

This week, the U.S. Preventive Services Task Force published a new draft guideline on breast cancer screening.1 The task force is considered the most rigorous and orthodox authority on the interpretation and application of the medical literature.The panel is widely respected for its expertise in epidemiology, screening, clinical trials interpretation, and structured reviews of the...

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Byline
Otis W. Brawley, MD, MACP, FRCP(L)
Bloomberg Distinguished Professor of Oncology and Epidemiology, Johns Hopkins University
Table of Contents

YOU MAY BE INTERESTED IN

Drugs & Targets

FDA approves new alternative standard related to mammography report assessments

FDA recently approved Alternative Standard #25 related to the Mammography Quality Standards Act. Alternative Standard #25 allows the interpreting physician to provide an assessment of “Incomplete: Need additional imaging evaluation” for the follow-up report issued within 30 calendar days of an initial report that received an assessment of “Incomplete: Need prior mammograms for comparison.”
Byline
Otis W. Brawley, MD, MACP, FRCP(L)
Bloomberg Distinguished Professor of Oncology and Epidemiology, Johns Hopkins University
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account